ClinicalTrials.gg
Status unknownNCT03973112Updated Jan 12, 2022

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

A Phase 2 interventional study of HLX10 3mg/kg and HLX04 5mg/kg in Hepatocellular Carcinoma, sponsored by Shanghai Henlius Biotech. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
379th of 1,034
123 · median 78
Started
2019
with 109 others
Phase 2
331 of 1,310
144 open now
Registered
415th of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 379th largest by enrollment of the 1,034 interventional ones that give a count, is one of 110 that started in 2019, is one of 331 in phase 2, and was the 415th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX10 + HLX04 intravenous infusion, every two weeks, lose treatment until clinical benefit, toxicity, the subjects of the resistance or the doctor decided to suspend the treatment, tested subjects death revocation of informed consent, subjects, subjects of pregnancy, not to plan or program requirement from, or management reasons, treatment for up to 2 years (before).

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who meet all of the following criteria are allowed to be enrolled into this study:

    • Volunteer to participate in clinical research;To fully understand and understand this study and to sign the Form (ICF);Willing to follow and able to complete all test procedures.
    • The age of signing ICF is ≥ 18 years old and ≤ 75 years old.
    • Subjects with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology, or clinically diagnosed as meeting the criteria for hepatocellular carcinoma of the American association of liver diseases (AASLD).
    • arm A、B Failure or intolerable toxicity after at least one standard systemic treatment for advanced hepatocellular carcinoma.Previous standard first-line systemic therapy included sorafenib, renvastinib and oxaliplatin based chemotherapy.
    • arm D never used systemic treatment
    • Barcelona Clinic Liver Cancer (BCLC) (appendix I) stage C;BCLC stage B patients who are not suitable for locoregional therapy may also be enrolled.
    • At least one assessed by IRRC according to v1.1 (appendix ii) has not been treated locally for this lesion (e.g., radiotherapy, radiofrequency ablation, TACE, ultrasound focusing knife, etc.).
    • The end of previous systematic treatment must be ≥ 2 weeks after the first medication in this study, and the treatment-related AE should be restored to the level of ci - ≤ 1 (except hair loss).
    • liver function rating within 7 days before the first administration of the study drug (appendix iii) : grade A and good grade B (≤ 7 points).
    • The physical performance score (appendix iv) for the 7 days prior to the first administration of the study drug was 0 or 1.
    • Expected survival ≥ 12 weeks.
    • Subjects of (-) and HBcAb (-) were admitted into the group;If HBsAg (+) or HBcAb (+), hbv-dna must be ≤ 500 IU/mL to be included in the group, and those with elevated hbv-dna must agree to receive nucleoside anti-hepatitis b virus treatment.Subjects with negative antibody (-) or hcv-rna were admitted.If hcv-rna is positive, subjects must have and AST ≤ 3× to be enrolled.Subjects with co-infection of hepatitis b and c should be excluded.
    • Major organs function normally and meet the following criteria (no blood transfusion, albumin, recombinant human thrombogenin or colony stimulating factor (CSF) treatment was received within 14 days prior to the first administration of this study)
    • Female subjects must meet:

Menopause (defined as having not had menstruation for at least 1 year and having no other known cause other than menopause), or Surgical sterilization (removal of ovaries and/or uterus), or have fertility, but must meet: serum pregnancy test must be negative within 7 days prior to first administration, and , agreed to the annual failure rate \< 1% of or abstinence (avoid heterosexual intercourse) (from signed informed consent to test drugs at the end of the time at least 120 days) after the treatment (annual failure rate \< 1% of contraceptive methods including bilateral tubal ligation, male sterilization techniques, the correct use can inhibit ovulation hormonal contracepties, releasing hormone of intrauterine contraceptive device and copper intrauterine contraceptive device), and do not breastfeed.

  • Male subjects must be satisfied: agree with abstinence (avoid heterosexual intercourse) or contraceptive measures, the rules are as follows: spouse or partner has been pregnant for childbearing age women, male subjects must be at the end of the experiment during drug dosage and drug time at least 120 days after the treatment, keep abstinence or use condoms for birth control in order to prevent drug exposure in the embryo.The duration of the clinical study and the reliability of the subjects' preferences and daily lifestyle measures of abstinence should be considered.Regular abstinence (e.g., calender days, ovulation, basal body temperature, or post-ovulation methods) and ejaculation are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria are not allowed to be enrolled in this study:

    • Hepatobiliary duct cell carcinoma, mixed cell carcinoma, or fibroblastic layer cell carcinoma are known.
    • Other active within 5 years prior to the first administration of the study drug.Curable localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma in situ of the prostate, cervical carcinoma in situ, and carcinoma in situ of the breast, can be included in the group.
    • People who are ready to undergo or have received organ or bone marrow transplants.
    • After appropriate intervention, uncontrollable pleural effusion, pericardial effusion or ascites still need to be drained frequently (once a month or more frequently).
    • Symptomatic, untreated, or progressive central nervous system (CNS) or meningeal .Asymptomatic subjects treated for CNS lesions can be enrolled if all of the following criteria are met:

      1. in addition to CNS, there must be lesions that can be measured according to v1.1;
      2. the patient had no history of intracranial or spinal bleeding;
      3. metastatic lesions were limited to cerebellum or supratentorial areas (i.e., no mesencephalon, pons, medulla or spinal cord metastatic lesions);
      4. there was no evidence of progress between the completion of CNS oriented therapy and the start of research and treatment;
      5. the patients did not receive stereotactic radiotherapy within 7 days before the study treatment, did not receive whole-brain radiotherapy within 14 days before the study treatment, and did not receive neurosurgical resection within 28 days before the study treatment;
      6. patients have no need for continuous use of in the treatment of CNS diseases.Stable doses of anticonvulsant therapy are permitted;
      7. asymptomatic patients with newly detected during screening are eligible to participate in the study after receiving radiotherapy or surgical treatment, and there is no need to repeat screening of brain scan results.
    • Cerebrovascular accident, myocardial infarction, unstable angina pectoris and poorly controlled arrhythmia occurred within half a year (including ≥ 450 ms for men and ≥ 470 ms for women) (QTc interval was calculated by Fridericia formula).
    • According to the (NYHA) standard (appendix 5) levels Ⅲ or Ⅳ cardiac insufficiency or heart colour to exceed examination: , left ventricular ejection fraction \< 50%.
    • A history of hepatic encephalopathy.
    • According to the images, portal vein invasion, inferior vena cava or cardiac involvement of HCC main portal branch (Vp4) were present.Patients with cancer thrombus in main portal vein but smooth blood flow in contralateral branch can be enrolled.
    • Involving major airways, vessels, or large mediastinal mass located centrally (\< 30 mm from the crest).
    • (HIV) infection.
    • Active tuberculosis.
    • Patients with previous and current cases of interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe impairment of lung function that may interfere with the detection and management of suspected drug-related lung toxicity.
    • Known activity or disease or history.
    • The study drug was treated with within 28 days prior to its first administration.
    • Subjects requiring systemic treatment with corticosteroids (> 10 mg/ day or equivalent dose of prednisone) or other within 14 days prior to or during the study.In the absence of active autoimmune disease, the inhalation or topical use of steroids, or adrenal hormone replacement at doses less than 10 mg/ day of prednisone efficacy, is permitted.
    • Within 14 days prior to the first administration of the study drug, any active infection requiring systematic anti-infective treatment occurs.
    • Major surgery was performed within 28 days prior to the first administration of the study drug. Major surgery in this study was defined as the minimum recovery time of 3 weeks after surgery before the surgery treated in this study could be performed.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    HLX10 3 mg/kg + HLX04 5 mg/kg

    HLX10 3 mg/kg + HLX04 5 mg/kg, as second-line treatment or above

    Drug: HLX10 3mg/kg · Drug: HLX04 5mg/kg

  • Experimental
    HLX10 3 mg/kg + HLX04 10 mg/kg

    HLX10 3 mg/kg + HLX04 10 mg/kg,as second-line treatment or above

    Drug: HLX10 3mg/kg · Drug: HLX04 10mg/kg

  • Experimental
    HLX10

    HLX10 3mg/kg, as second-line treatment or above

    Drug: HLX10 3mg/kg

  • Experimental
    HLX10+HLX04 1L treatment

    HLX10 3 mg/kg + HLX04 10 mg/kg: as first-line treatment

    Drug: HLX10 3mg/kg · Drug: HLX04 10mg/kg

Interventions

  • DrugHLX10 3mg/kg

    Drug page: Serplulimab

    anti-PD-1

  • DrugHLX04 5mg/kg

    Drug page: HLX04

    anti-VEGF, a biosimilar to Avastin

  • DrugHLX04 10mg/kg

    Drug page: HLX04

    anti-VEGF, a biosimilar to Avastin

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent radiological review

    Time frame: up to 2 years

Secondary outcomes

  1. ORR

    Objective response rate (assessed by the investigators based on the RECISTv1.1

    Time frame: up to 2 years

  2. 12-month OS rate

    12-month overall survival rate

    Time frame: from the date of first dose unitl the date of 12-month

  3. OS

    Overall survival (OS)

    Time frame: from the date of first dose unitl the date of death from any cause,assessed up to 2 years

  4. 12-month PFS rate

    12-month progression-free survival (PFS) rate

    Time frame: the proportion of subjects who have time interval over 12 months between the first dose and disease progression or death

  5. PFS

    Progression-free survival (assessed by independent radiological review

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

  6. PFS

    Progression-free survival (assessed by the investigators based on RECIST v1.1)

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

  7. DOR

    Duration of response

    Time frame: from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years

07

Study locations

1 site
  • Ethics committee of zhongshan hospital affiliated to fudan university
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Jun 2022, 32 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 32 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2019
First posted
Jun 4, 2019
StartActual
Sep 24, 2019
Primary completionEst.
Jun 15, 2022
CompletionEst.
Dec 15, 2022
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03973112
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Sep 24, 2019
Primary completion
Jun 15, 2022 (estimated)
Completion
Dec 15, 2022 (estimated)
Last update
Jan 12, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion